Novartis and Amgen already filed their migraine drug Aimovig (erenumab) with the FDA in late July, the first from the calcitonin gene-related peptide (CGRP) inhibitor class to get a review.

That’s now out – and the answer is still no. The cost-effectiveness agency for England and Wales says it can’t recommend routine NHS use of Aimovig (erenumab) for people suffering at least ...

In the US study, 30 adults with severe rosacea were given the migraine drug erenumab. The jab blocks the effect of a protein which is linked to the debilitating headaches and nausea of migraine.